David Lescuyer joins SkyePharma as Executive Vice President, Oral Business

He will be responsible for Skyepharma’s Oral Business including, after 30 June, the manufacturing operations in Saint-Quentin Fallavier, France

SkyePharma, an oral and inhalation drug development company, has hired David Lescuyer as Executive Vice President, Oral Business, reporting to Peter Grant, CEO.

Lescuyer will be responsible for SkyePharma’s Oral Business including, once the lease with Aenova, has expired on 30 June, the manufacturing operations in Saint-Quentin Fallavier, near Lyon, France.

With immediate effect, Guy Vergnault, Vice President, Oral Drug Delivery Solutions, will report to Lescuyer.

Lescuyer joins from Patheon Pharmaceuticals where he was Executive Director and General Manager, Patheon France and more recently Global VP, Operational Excellence.

Prior to Patheon, Lescuyer worked at Fareva, Cenexi and Catalent in senior operational and general management roles.

You may also like

Drug Delivery

SkyePharma signs exclusive licensing agreement to access Lucideon’s abuse deterrent drug delivery technology

First product to be developed for the growing $11bn US opioid market
Research & Development

Skyepharma acquires novel inhaled therapy platform

New product opportunity to be developed as an anti-inflammatory treatment for COPD
Manufacturing

Aenova agrees to employ former SkyePharma staff

Will expand its oral product development activities in Muttenz, Switzerland
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Subscribe now